Lunai Bioworks Inc. (LNAI)
$1.03-7.21%Close
SELLCRISIS · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $5M
- Beta
- 0.35
- P/E (TTM)
- -0.02
- Short % float
- 5.88%
- Days to cover
- 2.6
- SI change
- +10.8%
- 1W
- -8.85%
- 1M
- -52.53%
- vs SPY 1W
- -8.71%
- vs SPY 1M
- -55.04%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 10
- GROWTH
- 0
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC3.4%
REV YoY-
ROE5.7%
EPS YoY-
ROA-1.3%
GROSS-361
OP-46992
NET-612568
[VALUATION]
P/E TTM-0.02
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-0.00
P/FCF-
EV/EBITDA2.91
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.11
ND/EBITDA-
BETA0.35
Company news
FAQ
- What is LOPJLB’s current signal on LNAI?
- LOPJLB’s latest quantitative signal on Lunai Bioworks Inc. (LNAI) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is LNAI in?
- Lunai Bioworks Inc. (LNAI) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Lunai Bioworks Inc. (LNAI) do?
- Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."